[The efficacy of imatinib mesylate for patients with myeloproliferative neoplasm (MPN) with eosinophilia].

Abstract

OBJECTIVES:

To evaluate the efficacy and safety of imatinib mesylate (imatinib) for myeloproliferative neoplasm (MPN) patients with eosinophilia.

METHODS:

Eight MPN patients with eosinophilia and positive FIP1L1-PDGFR alpha gene and one CEL, NOS were treated with 100 mg or 400 mg/d imatinib orally.

RESULTS:

Hematological remission (HR) rate was 100%, including complete HR (CHR) rate 87.5%, and partial remission (PR) rate 12.5% with a median follow-up of 16 (6.0 -26.0 ) months. Complete molecular remission (cMR) rate was 85.7%. The median time of FIP1L1-PDGFR alpha fusion gene becoming negative was 4 (1.5 - 8) months. Three patients withdrew imatinib after getting cMR. After a median follow-up of 12 months, all the 3 patients remained in CHR. The main adverse effect of imatinib was mild myelosuppression occurring in 37.5% of patients in a median time of 6 (4 - 9) days after treatment.

CONCLUSION:

Imatinib in treatment of MPN with eosinophilia and positive FIP1L1-PDGFR alpha gene patients can induce high hematologic and molecular remission. The adverse effects of imatinib are mild and tolerable.

• Authors: Yue Zhang, Tie-Jun Qin, Chun-Lin Zhou, Liang Liu, Zhi-Jian Xiao
• Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi (Zhonghua Xue Ye Xue Za Zhi) Vol. 30 Issue 6 Pg. 381-4 (Jun 2009) ISSN: 0253-2727 [Print] China
• PMID: 19951530 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Benzamides
• Oncogene Proteins, Fusion
• Piperazines
• Pyrimidines
• mRNA Cleavage and Polyadenylation Factors
• Imatinib Mesylate
• FIP1L1-PDGFRA fusion protein, human
• Receptor, Platelet-Derived Growth Factor alpha

Topics

• Adult
• Aged
• Benzamides
• Eosinophilia (complications)
• Follow-Up Studies
• Humans
• Imatinib Mesylate
• Male
• Middle Aged
• Myeloproliferative Disorders (complications, drug therapy, genetics)
• Oncogene Proteins, Fusion (genetics)
• Piperazines (therapeutic use)
• Pyrimidines (therapeutic use)
• Receptor, Platelet-Derived Growth Factor alpha (genetics)
• Treatment Outcome
• Young Adult
• mRNA Cleavage and Polyadenylation Factors (genetics)